Use of tranexamic acid in melasma
Journal Title: Український журнал дерматології, венерології, косметології - Year 2019, Vol 0, Issue 3
Abstract
Tranexamic acid (TA) is an old drug used for a long time to treat or prevent excessive blood loss. In the beginning of the 1950s it was discovered that the amino acid lysine was able to inhibit activation of plasminogen, but the effect was too weak to be a candidate for the treatment of fibrinolytic haemorrhagic conditions. The first mention of TA in dermatology was in 1979 in actinic prurigo, with good results. Later it was demonstrated in vitro that TA was able to block melanogenesis. During the 2010’s more and more trials were published, assessing its efficacy in melasma, but also in erythrotelangiectasic rosacea. First, systemic TA was prescribed, but soon, because of the rare but severe complications susceptible of occurring, topical way was tested, giving similar results without risk of side effects. The particular interest of TA in the management of melasma is due to that it displays an activity at various levels. First, TA was shown to downregulate the activity of mast cells and consequently the release of histamine. Following the review of the currently available literature concerning the use of TA in melasma, it appears that this active ingredient permits achieving a good efficacy in this indication where there is no satisfactory therapy, with minor side effects. There are mainly three modalities of treatment of melasma with TA: oral administration and intradermal and topical applications. From the literature reviewed, it appears that the best results can be achieved by intradermal administration of TA (4 mg/l monthly) or topical 3 % TA (2/day). At this stage, the limitations of the currently available data are double: first, most of studies are concerning Asian skin, and secondly there is a lack of a large scale comparative study encompassing these three different ways of administration, which could confirm (or not) our analysis of currently published data.
Authors and Affiliations
C. Diehl
Keywords
Related Articles
- EP ID EP672779
- DOI 10.30978/UJDVK2019-3-104
- Views 93
- Downloads 0
GLOBIAD categorisation tool for monitoring of Incontinence-associated dermatitis
Objective — to determine the categories of GLOBIAD in patients with incontinenceassociated dermatitis (IAD) and to evaluate the effectiveness of topical use of camphor racemic solution in concentration of 0.1 g in 1 ml...
Efficiency and tolerability of drug AEvit in complex treatment of patients with atopic dermatitis
Objective — to evaluate the effectiveness and tolerability of drug AEvit in the complex treatment of patients with atopic dermatitis (AD). Materials and methods. We observed 100 patients with AD, who were randomized int...
Application of the blood autoplasm electrophoresis method in the programs of skin care
Objective — the development and implementation of a method for stimulation of subdermal regeneration processes in patients with aging or problematic skin. Materials and methods. A new method of blood autoplasm electroph...
Psoriasis: the choice of optimal topical corticosteroid drug
Psoriasis is an immune-mediated skin disease that occupies one of the leading positions in the morbidity structure of the population of Ukraine. The main mechanism of triggering immunopathological processes in the skin i...
Some aspects of use of desloratadine in treatment of chronic urticaria
Objecive — to investigate the clinical effectiveness of the antihistamine of II- generation Eslotin (desloratadine) in the treatment of chronic urticaria, the effect on the quality of life and the safety of therapy of p...